Share on LinkedInShare on LinkedIn

ARTICLE · 22 FEBRUARY 2010

Polpharma Can Acquire Part Of Bioton

Polpharma’s acquisition of part of Bioton has been approved by UOKiK.

PolandCorporate/Commercial Law
Malgorzata Urbańska
Malgorzata Urbańska
Mikolaj Piaskowski
Mikolaj Piaskowski

Polpharma's acquisition of part of Bioton has been approved by UOKiK.

Polpharma SA is Polish manufacturer of drugs and active pharmaceutical ingredients. Bioton SA produces mainly pharmaceuticals used for injections, including recombined human insulin and other biotechnological drugs.

Polpharma is acquiring the part of its business relating to Biodacyna, a drug used to treat eye infections.

Polish competition law requires UOKiK to be notified of an intended merger where the combined turnover of the merging parties in the preceding financial year exceeds €1 billion worldwide or €50 million in Poland.

This article was written for Law-Now, CMS Cameron McKenna's free online information service. To register for Law-Now, please go to www.law-now.com/law-now/mondaq

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from